Ian Walters, Portage Biotech CEO

Bris­tol My­ers vets tie up an­oth­er all-stock deal, lin­ing up clin­i­cal-stage on­col­o­gy pipeline

A hand­ful of Bris­tol My­ers Squibb vets set­ting up a fledg­ling can­cer drug de­vel­op­er have wrapped back-to-back stock deals to cre­ate a new on­col­o­gy pipeline.

Portage Biotech is helmed by CEO Ian Wal­ters and CSO Robert Kramer, and backed by three biotech en­tre­pre­neurs — UK in­vestor Jim Mel­lon, ex-Bio­haven board mem­ber De­clan Doogan and ear­ly Medi­va­tion backer Greg Bai­ley — who have whipped up a whole slate of dif­fer­ent ven­tures aimed at drug de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA